Conferences
ASBRS2025
We were pleased to present at ASBRS2025 in Las Vegas, where we shared new clinical findings from the Digistain® programme. Our presentation included an abstract
We were pleased to present at ASBRS2025 in Las Vegas, where we shared new clinical findings from the Digistain® programme. Our presentation included an abstract
We were honoured to recently host Professor Samuel Haryono from the Siloam Group Indonesia during his visit to the Digistain research lab at Imperial College
Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024. The first abstract presented data from Charing Cross
We’re thrilled to announce that Digistain® is now available to selected UK private patients, with reimbursement available though Bupa, WPA Health Insurance & Healix. Tim
We’re proud to share that our clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of
We are thrilled to share the announcement today that Digistain® are 1 of 4 FINALISTS for the 2024 Nature Spin-off Prize Over 150 innovative technologies
We are delighted to be in Abu Dhabi this week attending Abu Dhabi Global Healthcare Week with a UK delegation of NHS Organisations and digital
Wonderful to be named as a 2024 finalist in the EIT Health Catapult Competition. From 100s of companies considered ➡️ to 30 semi-finalists ➡️ to
London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years)
We are the finalists of Health Tech Challengers 2023. Join us at the event
We take pride in our involvement with SpinOff Bulgaria, a program dedicated to nurturing innovation and promoting entrepreneurial spirit.
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.
